ROYALTY PHARMA PLC- CL A (RPRX)
GB00BMVP7Y09 - Common Stock
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate...
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Royalty Pharma Reports Third Quarter 2024 Results
Royalty Pharma Reports Third Quarter 2024 Results
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million...
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire.
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial...
Royalty Pharma Declares Fourth Quarter 2024 Dividend
Royalty Pharma Declares Fourth Quarter 2024 Dividend
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
2 No-Brainer Dividend Stocks to Buy With $100 in October
With their high yields and strong underlying businesses, these stocks are hard to pass up.
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Now could be a great time to scoop up three stocks trading way below their previous peaks.
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
These dividend payers could more than double their payouts in the decade ahead.
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and...
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan...
Royalty Pharma Larger Than S&P 500 Component Jabil
First Week of April 2025 Options Trading For Royalty Pharma (RPRX)
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) just reported results for the second quarter of 20...
Royalty Pharma Reports Second Quarter 2024 Results
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice...
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial...
Royalty Pharma Declares Third Quarter 2024 Dividend
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...